Artisan Global Equity Fund Q3 2026 Portfolio Review

The portfolio underperformed the MSCI All Country World Index in Q3 2026, while health care stock selection significantly outperformed the benchmark’s holdings in that sector. Portfolio activity continued to center on electrification, financials, and aerospace and defense; no performance magnitude was reported.

Analysis

The only actionable signal is that healthcare stock selection helped while the portfolio still lagged ACWI. That does not establish healthcare as a durable overweight: the net result could reflect allocation, other-sector selection, or interaction effects, and the article provides no contribution data. Themed exposure to electrification, financials, and aerospace/defense may also load on overlapping macro factors—rates, capital spending, credit conditions, and government budgets—so apparent diversification by theme may not equal diversification by risk.

Near term, avoid extrapolating one quarter of healthcare selection or making a broad thematic pivot from aggregate relative performance. Over 1–3 months, the key catalyst is a holdings-level attribution review: identify whether lag came from allocation or selection and whether it was concentrated in a few positions. Over 6–18 months, the themes remain exposed to different reversal channels: delayed grid and industrial investment, tighter credit or weaker loan quality, and changes in defense procurement. No company-level valuation or earnings conclusion is supportable from the available information. The contrarian point is that headline underperformance may conceal repeatable selection skill—or, conversely, healthcare outperformance may be isolated and insufficient to offset persistent thematic factor risk.

Key Decisions for Investors

• Do not initiate a healthcare overweight or unwind the three themes based on this report alone. Request sector and security contribution, active weights, benchmark-relative risk, and attribution split between allocation, selection, and interaction before changing exposure.
• For the next 1–3 months, monitor whether relative weakness is concentrated in rate-sensitive electrification exposure, financials, or defense; treat any proposed rebalance as conditional on the portfolio’s actual holdings and risk contribution, which are not provided.
• Use a review trigger: if the next reporting period shows continued benchmark-relative losses from the same theme or a deterioration in the portfolio’s stated thesis metrics, reduce that active risk; if losses reverse and attribution confirms broad-based selection rather than a one-off position, retain exposure rather than chasing the healthcare result.
• No specific security or options trade is justified by the available data. The thesis is falsified as a persistent-underperformance concern if subsequent attribution shows the Q3 lag was temporary, diversified across positions, and not accompanied by adverse revisions to underlying investment theses.